请输入您要查询的百科知识：

　

词条 Usher syndrome
释义

  1. Types

     Usher syndrome I  Usher syndrome II  Usher syndrome III 

  2. Symptoms

  3. Cause

  4. Pathophysiology

  5. Diagnosis

     Classification 

  6. Treatment

  7. Epidemiology

  8. History

  9. Notable cases

  10. References

  11. Further reading

  12. External links

{{Infobox medical condition (new)
| name = Usher syndrome
| synonyms =
| image = autorecessive.svg
| caption = Usher syndrome is inherited in an autosomal recessive pattern. The genes implicated in Usher syndrome are described below.
| pronounce =
| field =
| symptoms =
| complications =
| onset =
| duration =
| types =
| causes =
| risks =
| diagnosis =
| differential =
| prevention =
| treatment =
| medication =
| prognosis =
| frequency =
| deaths =
}}

Usher syndrome, also known as Hallgren syndrome, Usher–Hallgren syndrome, retinitis pigmentosa–dysacusis syndrome or dystrophia retinae dysacusis syndrome,[1] is a rare genetic disorder caused by a mutation in any one of at least 11 genes resulting in a combination of hearing loss and visual impairment. It is the majority cause of deafblindness and is at present incurable.

Usher syndrome is classed into three subtypes (I, II and III) according to the genes responsible and the onset of deafness. All three subtypes are caused by mutations in genes involved in the function of the inner ear and retina. These mutations are inherited in an autosomal recessive pattern.

The occurrence of Usher syndrome varies across the world and across the different syndrome types, with rates as high as 1 in 12,500 in Germany[2] to as low as 1 in 28,000 in Norway.[3] Type I is most common in Ashkenazi Jewish and Acadian populations, while type III is rarely found outside Ashkenazi Jewish and Finnish[2] populations. Usher syndrome is named after Scottish ophthalmologist Charles Usher, who examined the pathology and transmission of the syndrome in 1914.

Types

Usher syndrome I

People with Usher I are born profoundly deaf and begin to lose their vision in the first decade of life. They also exhibit balance difficulties and learn to walk slowly as children, due to problems in their vestibular system.

Usher syndrome type I can be caused by mutations in any one of several different genes: CDH23, MYO7A, PCDH15, USH1C and USH1G. These genes function in the development and maintenance of inner ear structures such as hair cells (stereocilia), which transmit sound and motion signals to the brain. Alterations in these genes can cause an inability to maintain balance (vestibular dysfunction) and hearing loss. The genes also play a role in the development and stability of the retina by influencing the structure and function of both the rod photoreceptor cells and supporting cells called the retinal pigmented epithelium. Mutations that affect the normal function of these genes can result in retinitis pigmentosa and resultant vision loss.

Worldwide, the estimated prevalence of Usher syndrome type I is 3 to 6 per 100,000 people in the general population. Type I has been found to be more common in people of Ashkenazi Jewish ancestry (central and eastern European) and in the French-Acadian populations (Louisiana).

Usher syndrome II

People with Usher II are not born deaf and are generally hard-of-hearing rather than deaf, and their hearing does not degrade over time; moreover, they do not seem to have noticeable problems with balance. They also begin to lose their vision later (in the second decade of life) and may preserve some vision even into middle age.

Usher syndrome type II may be caused by mutations in any of three different genes: USH2A, GPR98 and DFNB31. The protein encoded by the USH2A gene, usherin, is located in the supportive tissue in the inner ear and retina. Usherin is critical for the proper development and maintenance of these structures, which may help explain its role in hearing and vision loss. The location and function of the other two proteins are not yet known.

Usher syndrome type II occurs at least as frequently as type I, but because type II may be underdiagnosed or more difficult to detect, it could be up to three times as common as type I.

Usher syndrome III

People with Usher syndrome III are not born deaf but experience a "progressive" loss of hearing, and roughly half have balance difficulties.

Mutations in only one gene, CLRN1, have been linked to Usher syndrome type III. CLRN1 encodes clarin-1, a protein important for the development and maintenance of the inner ear and retina. However, the protein's function in these structures, and how its mutation causes hearing and vision loss, is still poorly understood.

The frequency of Usher syndrome type III is only significant in the Finnish population[2] as well as the population of Birmingham, UK, [3] and individuals of Ashkenazi Jewish heritage. It has been noted rarely in a few other ethnic groups.

Symptoms

Usher syndrome is characterized by hearing loss and a gradual visual impairment. The hearing loss is caused by a defective inner ear, whereas the vision loss results from retinitis pigmentosa (RP), a degeneration of the retinal cells. Usually, the rod cells of the retina are affected first, leading to early night blindness (nyctalopia) and the gradual loss of peripheral vision. In other cases, early degeneration of the cone cells in the macula occurs, leading to a loss of central acuity. In some cases, the foveal vision is spared, leading to "doughnut vision"; central and peripheral vision are intact, but an annulus exists around the central region in which vision is impaired.

Cause

{{Legend inline|#EECCCC|Type I}} {{Legend inline|#D1EEEE|Type II}} {{Legend inline|#EEEED1|Type III}}
Table 1: Genes linked to Usher syndrome
Type Freq[4]Gene locus GeneProtein Function Size (AA) UniProtOMIM
USH1B39–55%11q13.5MYO7AMyosin VIIAMotor protein2215{{uniprot|Q13402}}{{OMIM2|276900}}
USH1C6–7%11p15.1-p14USH1CHarmoninPDZ-domain protein552{{uniprot|Q9Y6N9}}{{OMIM2|276904}}
USH1D19–35%10q21-q22CDH23Cadherin 23Cell adhesion3354{{uniprot|Q9H251}}{{OMIM2|601067}}
USH1Erare21q21?????{{OMIM2|602097}}
USH1F11–19%10q11.2-q21PCDH15Protocadherin 15Cell adhesion1955{{uniprot|Q96QU1}}{{OMIM2|602083}}
USH1G7%17q24-q25USH1G SANSScaffold protein461{{uniprot|Q495M9}}{{OMIM2|606943}}
USH2A80%1q41USH2AUsherinTransmembrane linkage5202{{uniprot|O75445}}{{OMIM2|276901}}
USH2C15%5q14.3-q21.1GPR98VLGR1bVery large GPCR6307{{uniprot|Q8WXG9}}{{OMIM2|605472}}
USH2D5%9q32-q34DFNB31WhirlinPDZ-domain protein907{{uniprot|Q9P202}}{{OMIM2|611383}}
USH3A100%3q21-q25CLRN1Clarin-1Synaptic shaping232{{uniprot|P58418}}{{OMIM2|276902}}

Usher syndrome is inherited in an autosomal recessive pattern. Several genes have been associated with Usher syndrome using linkage analysis of patient families (Table 1) and DNA sequencing of the identified loci.[5][6] A mutation in any one of these genes is likely to result in Usher syndrome.

The clinical subtypes Usher I and II are associated with mutations in any one of six (USH1B-G) and three (USH2A ,C-D) genes, respectively, whereas only one gene, USH3A, has been linked to Usher III so far. Two other genes, USH1A and USH2B, were initially associated with Usher syndrome, but USH2B has not been verified and USH1A was incorrectly determined and does not exist.[7] Research in this area is ongoing.

Using interaction analysis techniques, the identified gene products could be shown to interact with one another in one or more larger protein complexes. If one of the components is missing, this protein complex cannot fulfil its function in the living cell, and it probably comes to the degeneration the same. The function of this protein complex has been suggested to participate in the signal transduction or in the cell adhesion of sensory cells.[6]

A study shows that three proteins related to Usher syndrome genes (PCDH15, CDH23, GPR98) are also involved in auditory cortex development, in mouse and macaque. Their lack of expression induces a decrease in the number of parvalbumin interneurons. Patients with mutations for these genes could have consequently auditory cortex defects.[8]

{{Clear}}

Pathophysiology

The progressive blindness of Usher syndrome results from retinitis pigmentosa.[13][14] The photoreceptor cells usually start to degenerate from the outer periphery to the center of the retina, including the macula. The degeneration is usually first noticed as night blindness (nyctalopia); peripheral vision is gradually lost, restricting the visual field (tunnel vision), which generally progresses to complete blindness. The qualifier pigmentosa reflects the fact that clumps of pigment may be visible by an ophthalmoscope in advanced stages of degeneration.[15]

The hearing impairment associated with Usher syndrome is caused by damaged hair cells in the cochlea of the inner ear inhibiting electrical impulses from reaching the brain.

Diagnosis

Since Usher syndrome is incurable at present, it is helpful to diagnose children well before they develop the characteristic night blindness. Some preliminary studies have suggested as many as 10% of congenitally deaf children may have Usher syndrome.[1] However, a misdiagnosis can have bad consequences.

The simplest approach to diagnosing Usher syndrome is to test for the characteristic chromosomal mutations. An alternative approach is electroretinography, although this is often disfavored for children, since its discomfort can also make the results unreliable.[1] Parental consanguinity is a significant factor in diagnosis. Usher syndrome I may be indicated if the child is profoundly deaf from birth and especially slow in walking.

Thirteen other syndromes may exhibit signs similar to Usher syndrome, including Alport syndrome, Alström syndrome, Bardet–Biedl syndrome, Cockayne syndrome, spondyloepiphyseal dysplasia congenita, Flynn–Aird syndrome, Friedreich ataxia, Hurler syndrome (MPS-1), Kearns–Sayre syndrome (CPEO), Norrie syndrome, osteopetrosis (Albers–Schonberg disease), Refsum disease (phytanic acid storage disease) and Zellweger syndrome (cerebrohepatorenal syndrome).

Classification

Although Usher syndrome has been classified clinically in several ways,[9][10][11] the prevailing approach is to classify it into three clinical sub-types called Usher I, II and III in order of decreasing severity of deafness.[12][13] Although it was previously believed that there was an Usher syndrome type IV, researchers at the University of Iowa recently{{When|date=October 2018}} confirmed that there is no USH type IV.{{citation needed|date=February 2018}} As described below, these clinical subtypes may be further subdivided by the particular gene mutated; people with Usher I and II may have any one of six and three genes mutated, respectively, whereas only one gene has been associated with Usher III. The function of these genes is still poorly understood.

Usher syndrome is a variable condition; the degree of severity is not tightly linked to whether it is Usher I, II or III. For example, someone with type III may be unaffected in childhood but go on to develop a profound hearing loss and a very significant loss of sight by early-to-mid adulthood. Similarly, someone with type I, who is therefore profoundly deaf from birth, may keep good central vision until the sixth decade of life or even beyond. People with type II, who have useful hearing with a hearing aid, can experience a wide range of severity of the RP. Some may maintain good reading vision into their 60s, while others cannot see to read while still in their 40s.

Since Usher syndrome is inherited in an autosomal recessive pattern, both males and females are equally likely to inherit it. Consanguinity of the parents is a risk factor.

Treatment

Since Usher syndrome results from the loss of a gene, gene therapy that adds the proper protein back ("gene replacement") may alleviate it, provided the added protein becomes functional. Recent studies of mouse models have shown one form of the disease—that associated with a mutation in myosin VIIa—can be alleviated by replacing the mutant gene using a lentivirus.[14] However, some of the mutated genes associated with Usher syndrome encode very large proteins—most notably, the USH2A and GPR98 proteins, which have roughly 6000 amino-acid residues. Gene replacement therapy for such large proteins may be difficult.

Epidemiology

Usher syndrome is responsible for the majority of deafblindness.[15] It occurs in roughly 1 in 23,000 people in the United States,[16] 1 in 28,000 in Norway,[17] and 1 in 12,500 in Germany.[18] People with Usher syndrome represent roughly one-sixth of people with retinitis pigmentosa.[13]

History

Usher syndrome is named after the Scottish ophthalmologist Charles Usher, who examined the pathology and transmission of this illness in 1914 on the basis of 69 cases.[19] However, it was first described in 1858 by Albrecht von Gräfe, a pioneer of modern ophthalmology.[20] He reported the case of a deaf patient with retinitis pigmentosa, who had two brothers with the same symptoms. Three years later, one of his students, Richard Liebreich, examined the population of Berlin for disease pattern of deafness with retinitis pigmentosa.[21] Liebreich noted Usher syndrome to be recessive, since the cases of blind-deafness combinations occurred particularly in the siblings of blood-related marriages or in families with patients in different generations. His observations supplied the first proofs for the coupled transmission of blindness and deafness, since no isolated cases of either could be found in the family trees.

Animal models of this human disease (such as knockout mice and zebrafish) have been developed recently{{When|date=October 2018}} to study the effects of these gene mutations and to test potential cures for Usher syndrome.

Notable cases

The [https://www.usher-syndrome.org Usher Syndrome Coalition (USC)] is an international non-profit organization that provides information and support to individuals living with Usher syndrome, as well as their families.

  • A 31-year-old woman with Usher syndrome, Rebecca Alexander, was profiled in Marie Claire in November 2007.[22] After graduating from the University of Michigan with excellent marks, Alexander went on to Columbia University, where she earned two master's degrees in public health and clinical social work. She is an active member of her community, working with various charities in NYC. Alexander's dedication as an active member of her community was most notably recognized when she was selected as a "Community Hero" to run with the Olympic Torch for the 1996 Atlanta Olympic Games in honor of her volunteer work for Project Open Hand, a nonprofit organization delivering meals to people living with HIV/AIDS in the San Francisco Bay area. Alexander received her psychodynamic psychotherapy training through the American Institute of Psychoanalysis. She currently works in private practice specializing in the treatment of mood and anxiety disorders, eating disorders, addictions, disability, and trauma. While currently facilitating group seminars for the Foundation Fighting Blindness during national conferences, Rebecca is also in the process of launching the Usher III Initiative, a nonprofit organization dedicated to science and research that seeks to find a cure for Usher III. Alexander teaches indoor cycling/spin classes with a strong following at select gyms in New York City. She was featured on NBC's Today Show on March 20, 2009, which was nominated for an Emmy award in September 2010. She is the sister of NBC News National Correspondent Peter Alexander. She appeared again on the Today Show in September 2014 with her brother, and discussed her experiences with the disease and her book Not Fade Away: A Memoir of Senses Lost and Found.
  • Christine "Coco" Roschaert[23] was born in Ottawa, Ontario on 5 January 1980. She is a well-known person with Usher syndrome. She has published video blogs on YouTube,[24] and was the kick-off speaker for Deaf Awareness Week at the University of Vermont.[25] In 2006, she graduated with a degree in Communication Sciences from Gallaudet University; there, she was a hunger striker in the 2006 protest organized by the Gallaudet United Now Movement.[26] Roschaert was in Nigeria founding the first deafblind program in that country. Roschaert is now living in Quebec, Canada.
  • In 2007, Ginny Paja-Nyholm posted videos about her life with the condition on YouTube.[27]
  • In October 2007, Candice, a mom living in Texas, began blogging about her two daughters, Jasmine and Rebecca; Rebecca has Usher syndrome I.[28]
  • Catherine Fischer wrote a well-received autobiography of growing up with Usher syndrome in Louisiana, entitled Orchid of the Bayou.[29]
  • Vendon Wright has written two books describing his life with Usher syndrome, I was blind but now I can see[30] and Through my eyes.[31]
  • Louise Boardman has also written a short book called My son has Usher's Syndrome.[32]
  • Christian Markovic is an artist living with Usher syndrome, who runs a company, Fuzzy Wuzzy Designs.[33]
  • Spencer Tracy's son John Tracy was a well-known person with Usher syndrome who lived a full life.[34] The John Tracy Clinic was founded in 1942 by his mother Louise to offer free help to parents of hearing-impaired infants and preschool children.[1]
  • DNA helix co-discoverer and Nobel laureate James D. Watson has homozygous USH1B mutations, according to his published genome.[35] It is not clear why he did not develop the syndrome. This lack of genetic penetrance argues that expression of the phenotype of Usher syndrome may be more complex than originally assumed.
  • The Israeli Nalaga'at (do touch) Deaf-blind Acting Ensemble consists of 11 deaf-blind actors, most of whom are diagnosed with Usher syndrome. The theater group has put on several productions and appeared both locally in Israel and abroad in London and Broadway.[36]
  • Katie Kelly is a gold medal winning paralympian that was diagnosed in her early 20s. Katie was declared as legally blind in January 2015 and became classified as a vision impaired (PT5) paratriathlete in February 2015. Katie then went on to win National, World and Olympic titles in 2015 and 2016. In 2017, Kelly established the Sports Access Foundation to assist children with a disability with access to sport and recreational facilities.

References

1. ^1 2 3 {{cite journal |vauthors=Mets MB, Young NM, Pass A, Lasky JB | year = 2000 | title = Early diagnosis of Usher syndrome in children | journal = Transactions of the American Ophthalmological Society | volume = 98 | pages = 237–45 | pmid = 11190026 | pmc = 1298229}}
2. ^1 {{cite journal|vauthors=Pakarinen L, Tuppurainen K, Laipapala P, Mäntyjärvi M, Puhakka H|year=1996|title=The ophthalmological course of Usher syndrome type III|journal=International Ophthalmology|volume=19|issue=5|pages=307–311|doi=10.1007/BF00130927|pmid=8864816}}
3. ^{{cite journal|vauthors=Hope CI, Bundey S, Proops D, Fielder AR|year=1997|title=Usher syndrome in the city of Birmingham — prevalence and clinical classification|journal=British Journal of Ophthalmology|volume=81|issue=1|pages=46–53|doi=10.1136/bjo.81.1.46|pmc=1721995|pmid=9135408}}
4. ^{{cite journal |vauthors=Roux AF, Faugere V, Le Guedard S, Pallares-Ruiz N, Vielle A, Chambert S, Marlin S, Hamel C, Gilbert B, Malcolm S, Claustres M | year = 2006 | title = Survey of the frequency of USH1 gene mutations in a cohort of Usher patients shows the importance of cadherin 23 and protocadherin 15 genes and establishes a detection rate of above 90% | journal = J Med Genet | volume = 43 | pages = 763–768 | pmid = 16679490 | url = http://jmg.bmj.com/cgi/reprint/43/9/763 | doi = 10.1136/jmg.2006.041954 | issue = 9 | pmc = 2564578}}
{{cite journal |vauthors=Ouyang XM, Yan D, Du LL, Hejtmancik JF, Jacobson SG, Nance WE, Li AR, Angeli S, Kaiser M, Newton V, Brown SD, Balkany T, Liu XZ | year = 2005 | title = Characterization of Usher syndrome type I gene mutations in an Usher syndrome patient population | journal = Hum Genet |volume = 116 | pages = 292–299 | pmid = 15660226 | doi = 10.1007/s00439-004-1227-2 | issue = 4}}
5. ^{{cite journal | last1 = Petit | first1 = C | title = Usher syndrome: from genetics to pathogenesis | journal = Annual Review of Genomics and Human Genetics | volume = 2 | pages = 271–97 | year = 2001 | pmid = 11701652 | doi = 10.1146/annurev.genom.2.1.271 }}
6. ^1 {{cite journal | last1 = Reiners | first1 = J | last2 = Nagel-Wolfrum | first2 = K | last3 = Jürgens | first3 = K | last4 = Märker | first4 = T | last5 = Wolfrum | first5 = U | title = Molecular basis of human Usher syndrome: deciphering the meshes of the Usher protein network provides insights into the pathomechanisms of the Usher disease | journal = Experimental Eye Research | volume = 83 | issue = 1 | pages = 97–119 | year = 2006 | pmid = 16545802 | doi = 10.1016/j.exer.2005.11.010 }}
7. ^{{cite journal | last1 = Gerber | first1 = S | last2 = Bonneau | first2 = D | last3 = Gilbert | first3 = B | last4 = Munnich | first4 = A | last5 = Dufier | first5 = JL | last6 = Rozet | first6 = JM | last7 = Kaplan | first7 = J | title = USH1A: chronicle of a slow death | journal = American Journal of Human Genetics | volume = 78 | issue = 2 | pages = 357–9 | year = 2006 | pmid = 16400615 | pmc = 1380243 | doi = 10.1086/500275 }}
8. ^{{Cite journal|last=Libé-Philippot|first=Baptiste|last2=Michel|first2=Vincent|last3=Monvel|first3=Jacques Boutet de|last4=Gal|first4=Sébastien Le|last5=Dupont|first5=Typhaine|last6=Avan|first6=Paul|last7=Métin|first7=Christine|last8=Michalski|first8=Nicolas|last9=Petit|first9=Christine|date=2017-07-25|title=Auditory cortex interneuron development requires cadherins operating hair-cell mechanoelectrical transduction|journal=Proceedings of the National Academy of Sciences|language=en|volume=114|issue=30|pages=7765–7774|doi=10.1073/pnas.1703408114|issn=0027-8424|pmid=28705869|pmc=5544301}}
9. ^{{cite journal|author=Hammerschlag V|year=1907|title=Zur Kenntnis der hereditaer-degenerativen Taubstummen und ihre differential diagnostische Bedeutung|journal=Z. Ohrenheilk.|volume=54|pages=18–36}}
{{cite book|title=Retinitis Pigmentosa and Allied Diseases|author=Bell J|publisher=Cambridge University Press|year=1933|edition=2nd|location=London}}
{{cite journal|author=Hallgren B|year=1959|title=Retinitis pigmentosa combined with congenital deafness with vestibulo-cerebellar ataxia and mental abnormality in a proportion of cases: Clinical and geneto-statistical survey|journal=Acta Psychiatr Scand Suppl|volume=34|issue=138|pages=9–101|doi=10.1111/j.1600-0447.1959.tb08605.x|pmid=14399116}}
{{cite journal|vauthors=Merin S, Auerbach E|year=1976|title=Retinitis pigmentosa|journal=Surv. Ophthalmol.|volume=20|issue=5|pages=303–345|doi=10.1016/S0039-6257(96)90001-6|pmid=817406}}
{{cite book|title=The Heterogeneity of Usher Syndrome|vauthors=Davenport S, Omenn G|publisher=Excerpta Medica Foundation|year=1977|edition=volume 426|location=Amsterdam}}
{{cite journal|vauthors=Gorlin R, Tilsner T, Feinstein S, Duvall AJ|year=1979|title=Usher syndrome type III|journal=Arch. Otolaryngol.|volume=105|issue=6|pages=353–354|doi=10.1001/archotol.1979.00790180051011|pmid=454290}}
10. ^1 {{cite journal|vauthors=Fishman GA, Kumar A, Joseph ME, Torok N, Andersonj RJ|year=1983|title=Usher's syndrome|journal=Archives of Ophthalmology|volume=101|issue=9|pages=1367–1374|doi=10.1001/archopht.1983.01040020369005|pmid=6604514}}
11. ^{{cite journal|vauthors=Sankila EM, Pakarinen H, Kääriäinen H, Aittomäki K, Karjalainen S, Sistonen P, de la Chapelle A|year=1995|title=Assignment of Usher syndrome type III (USH3) gene to chromosome 3q|journal=Hum. Mol. Genet.|volume=4|issue=1|pages=93–98|doi=10.1093/hmg/4.1.93|pmid=7711740}}
12. ^1 {{cite journal|vauthors=Smith RJ, Berlin CI, Hejtmancik JF, Keats BJ, Kimberling WJ, Lewis RA, etal|year=1994|title=Clinical diagnosis of the Usher syndromes. Usher Syndrome Consortium|journal=American Journal of Medical Genetics|volume=50|issue=1|pages=32–38|doi=10.1002/ajmg.1320500107|pmid=8160750}}
13. ^1 2 {{cite journal|author=Williams DS|year=2007|title=Usher syndrome: Animal models, retinal function of Usher proteins, and prospects for gene therapy|journal=Vision Research|volume=48|issue=3|pages=433–41|doi=10.1016/j.visres.2007.08.015|pmc=2680226|pmid=17936325}}
14. ^{{cite journal |vauthors=Hashimoto T, Gibbs D, Lillo C, Azarian SM, Legacki E, Zhang XM, Yang XJ, Williams DS | year = 2007 | title = Lentiviral gene replacement therapy of retinas in a mouse model for Usher syndrome type 1B | journal = Gene Therapy | volume = 14 | pages = 584–594 | pmid = 17268537 | doi = 10.1038/sj.gt.3302897 | issue = 7 }}
15. ^{{cite journal|author=Vernon M|year=1969|title=Usher's syndrome — deafness and progressive blindness. Clinical cases, prevention, theory and literature survey|journal=Journal of Chronic Diseases|volume=22|issue=3|pages=133–151|doi=10.1016/0021-9681(69)90055-1|pmid=4897966}}
16. ^{{cite journal|vauthors=Boughman J, Vernon M, Shaver K|year=1983|title=Usher syndrome: Definition and estimate of prevalence from two high-risk populations|journal=Journal of Chronic Diseases|volume=36|issue=8|pages=595–603|doi=10.1016/0021-9681(83)90147-9|pmid=6885960}}
17. ^1 {{cite journal|author=Grøndahl J|year=1987|title=Estimation of prognosis and prevalence of retinitis pigmentosa and Usher syndrome in Norway|journal=Clin. Genet.|volume=31|issue=4|pages=255–264|doi=10.1111/j.1399-0004.1987.tb02804.x|pmid=3594933}}
18. ^1 {{cite journal|vauthors=Otterstedde CR, Spandau U, Blankenagel A, Kimberling WJ, Reisser C|year=2001|title=A new clinical classication for Usher's syndrome based on a new subtype of Usher's syndrome type I|journal=Laryngoscope|volume=111|issue=1|pages=84–86|doi=10.1097/00005537-200101000-00014|pmid=11192904}}
19. ^{{cite journal | author = Usher C | year = 1914 | title = On the inheritance of Retinitis pigmentosa with notes of cases | journal = Roy. Lond. Ophthalmol. Hosp. Rep. | volume = 19 | pages = 130–236}}
20. ^{{cite journal | author = von Gräfe A | year = 1858 | title = Exceptionelles Verhalten des Gesichtsfeldes bei Pigmententartung der Netzhaut | journal = Archiv für Ophthalmologie | volume = 4 | pages = 250–253}}
21. ^{{cite journal | author = Liebreich R | year = 1861 | title = Abkunft aus Ehen unter Blutsverwandten als Grund von Retinitis pigmentosa | journal = Dtsch. Klin. | volume = 13 | pages = 53}}
22. ^{{cite journal |vauthors=Alexander R, Grossman AJ |date=November 2007 | title = out of sight, out of sound | journal = Marie Claire | volume = 14 | issue = 11 | pages = 191–193}}
23. ^{{cite web|url=http://tactiletheworld.wordpress.com/|title=Tactile The World}}
24. ^{{cite av media|url=https://www.youtube.com/user/tactiletheworld|title=Coco Roschaert|publisher=|via=YouTube}}
25. ^ASL at UVM
26. ^{{cite web|url=http://www.xanga.com/tactilejunkie/545143343/item.html|title=Xanga 2.0 is Here!}}
27. ^{{cite av media|url=https://www.youtube.com/watch?v=e7yKsmO2qzI|title=An Usher Syndrome Trivia Challenge|date=23 April 2007|publisher=|via=YouTube}}
28. ^{{cite web | author = Candice | url = http://ushersmom.blogspot.com/ | title = I'm adopting a Deaf child with Ushers, now what? | accessdate = 2007-11-07}}
29. ^{{cite book |vauthors=Carroll C, Fischer CH | year = 2001 | title = Orchid of the Bayou: A Deaf Woman Faces Blindness | publisher = Gallaudet University Press | isbn = 978-1-56368-104-2}}
30. ^{{cite book | author = Wright V | year = 2007 | title = I was blind but now I can see | publisher = Authorhouse | isbn = 978-1-4208-9101-0}}
31. ^{{cite book | author = Wright V | year = 2007 | title = Through my eyes | publisher = Pipers' Ash Ltd | isbn = 978-1-904494-86-7}}
32. ^{{cite book | author = Boardman LS | year = 1985 | title = My son has Usher's Syndrome | publisher = Foundation Fighting Blindness | id = B0007207IG}}
33. ^{{cite web|url=http://www.fuzzywuzzydesign.com/about/|title=Who's Fuzzy|work=Fuzzy Wuzzy Design}}
34. ^{{cite web|url=http://www.presstelegram.com/news/ci_6160671|title=Obituary: Spencer Tracy's son dies at 82}}
35. ^{{cite journal|title=The Genetic Privacy of Presidential Candidates|doi=10.1056/NEJMp0808100 |pmid=19020322|pmc=2925179| volume=359|issue=21|journal=New England Journal of Medicine|pages=2192–2193|year=2008|author=Green RC, Annas GJ}}
36. ^http://www.nalagaat.org.il/home.php

Further reading

  • {{cite book |vauthors=Stiefel SH, Lewis RA | year = 1991 | title = The Madness of Usher's: Coping With Vision and Hearing Loss/Usher Syndrome Type II | publisher = Business of Living Publications | isbn = 978-1-879518-06-3}}
  • {{cite book |vauthors=Duncan E, Prickett HT | year = 1988 | title = Usher's Syndrome: What It Is, How to Cope, and How to Help | publisher = Charles C. Thomas | isbn = 978-0-398-05481-6}}
  • {{cite book | author = Vernon M | year = 1986 | title = Answers to your questions about Usher's syndrome (retinitis pigmentosa with hearing loss) | publisher = Foundation Fighting Blindness | id = ASIN B00071QLJ6}}
  • {{cite book | author = Vernon M | year = 1969 | title = Usher's syndrome: Deafness and progressive blindness : clinical cases, prevention, theory and literature survey | publisher = Pergamon Press | id = ASIN B0007JHOJ4}}

External links

{{Medical resources
| DiseasesDB = 13611
| ICD10 = 35.53
| ICD9 =
| ICDO =
| OMIM = 276900
| OMIM_mult = {{OMIM2|276901}}
| MedlinePlus =
| eMedicineSubj =
| eMedicineTopic =
| MeshID = D052245
| Orphanet = 886
}}
  • [https://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=usher1 GeneReviews/NCBI/NIH/UW entry on Usher Syndrome Type I]
  • [https://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=usher2 GeneReviews/NCBI/NIH/UW entry on Usher Syndrome Type II]
  • [https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=usher/ NCBI Genetic Testing Registry]
  • General overview from the NIH
  • [https://web.archive.org/web/20060416083222/http://www.nidcd.nih.gov/health/hearing/usher.htm Usher Syndrome] Information from the National Institute on Deafness and Other Communication Disorders (NIDCD).
  • [https://www.usher-syndrome.org/ Usher Syndrome Coalition]
{{Diseases of the ear and mastoid process}}{{Cytoskeletal defects}}

6 : Autosomal recessive disorders|Syndromes|Ashkenazi Jews topics|Cytoskeletal defects|Diseases of the ear and mastoid process|Rare diseases
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/12 11:27:12